DelveInsight’s, “TIM-3 Inhibitor - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TIM-3 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
TIM-3 Inhibitor: Overview
T-cell immunoglobulin and mucin domain 3 (Tim-3) is an immunoglobulin and mucin domain-containing cell surface molecule. The protein is characterized by a common structural organization consisting of an amino-terminal immunoglobulin variable domain (V domain) with five noncanonical cysteines, a mucin stalk, a transmembrane domain and a cytoplasmic tail. TIM-3 is known to interact with four ligands, galectin-9, phosphatidylserie (PtdSer), CEACAM-1and HMGB1 (high mobility group box-1). Tim-3 is a checkpoint receptor expressed by a wide variety of immune cells as well as leukemic stem cells. Various preclinical data support the therapeutic modulation of TIM3 in multiple disease contexts including autoimmunity, infection, and cancer. The blocking of Tim-3 and PD-1 together can result in reduced tumor progression in preclinical models and can improve antitumor T-cell responses in cancer patients.
The companies and academics are working to assess challenges and seek opportunities that could influence TIM-3 Inhibitor R&D. The therapies under development are focused on novel approaches for TIM-3 Inhibitor.
This segment of the TIM-3 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIM-3 Inhibitor Emerging Drugs
Cobolimab: GlaxoSmithKline
Cobolimab is a novel IgG4 anti-TIM-3 monoclonal antibody. It is under clinical investigation in clinical trial in combination with Dostarlimab and Docetaxel in Advanced Non-small cell lung cancer (NSCLC). By binding to and blocking TIM-3, Cobolimab allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth.
BMS-986258: Bristol-Myers Squibb
BMS-986258 (anti-TIM-3) is a fully-human monoclonal antibody targeting TIM-3 (T cell immunoglobulin and mucin domain-3). It is the first clinical candidate from the discovery collaboration between Five Prime Therapeutics and BMS that includes targets in three immune checkpoint pathways.
Further product details are provided in the report……..
This segment of the report provides insights about the different TIM-3 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the TIM-3 Inhibitor. The companies which have their TIM-3 Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Novarits Oncology.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
TIM-3 Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIM-3 Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIM-3 Inhibitor drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
TIM-3 Inhibitor: Overview
Pipeline Therapeutics
Therapeutic Assessment
TIM-3 Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
TIM-3 Inhibitor Collaboration Deals
Late Stage Products (Phase III)
Sabatolimab: Novarits Oncology
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BMS 986258: Bristol-Myers Squibb
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Sym 023: Symphogen
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
NB 002: Neologics Bioscience
Drug profiles in the detailed report…..
Inactive Products
TIM-3 Inhibitor Key Companies
TIM-3 Inhibitor Key Products
TIM-3 Inhibitor- Unmet Needs
TIM-3 Inhibitor- Market Drivers and Barriers
TIM-3 Inhibitor- Future Perspectives and Conclusion
TIM-3 Inhibitor Analyst Views
TIM-3 Inhibitor Key Companies
Appendix
List of Table
Table 1: Total Products for TIM-3 Inhibitor
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for TIM-3 Inhibitor
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Novarits
• GlaxoSmithKline
• Roche
• Incyte Corporation
• Bristol-Myers Squibb
• Novartis
• Interprotein
• TrueBinding
• Celgene
• Sutro Biopharma
• Neologics Bioscience
• Symphogen
